Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganetespib plus weekly paclitaxel in platinum‑resistant ovarian, fallopian tube or primary peritoneal cancer
DRKS00005501Phase 2Completed
- Sponsor
- Medical University of Innsbruck
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised trial of ganetespib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by Medical University of Innsbruck. Primary endpoints: Maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of ganetespib in combination with weekly paclitaxel, Safety and tolerability of ganetespib plus weekly paclitaxel and 1 more. Started Oct 2014; status: completed.
02
Drugs
ganetespib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on DRKS00005501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00005501.